Can Radiotherapy Empower the Host Immune System to Counterattack Neoplastic Cells? A Systematic Review on Tumor Microenvironment Radiomodulation
Authors:
- Federico IoriFIFederico Iori
- Alessio BruniABAlessio Bruni
- Salvatore CozziSCSalvatore Cozzi
- Patrizia CiammellaPCPatrizia Ciammella
- Francesca Di PressaFPFrancesca Di Pressa
- Luca BoldriniLuca Boldrini
- Carlo GrecoCGCarlo Greco
- Valerio NardoneVNValerio Nardone
- Viola SalvestriniVSViola Salvestrini
- Isacco DesideriIDIsacco Desideri
- Francesca De FeliceFFFrancesca De Felice
- Cinzia IottiCICinzia Iotti
Open Access
- 30 June 2022
- journal article
- review article
- Published by MDPI AG in Current Oncology
- Vol. 29 (7) , 4612-4624
Abstract
Despite the rising evidence in favor of immunotherapy (IT), the treatment of oncological patients affected by so-called “cold tumors” still represents an open issue. Cold tumors are characterized by an immunosuppressive (so-called cold) tumor microenvironment (TME), which favors host immune system suppression, cancer immune-escape, and a worse response to IT. However, the TME is not a static element, but dynamically mutates and can be changed. Radiotherapy (RT) can modulate a cold microenvironment, rendering it better at tumor killing by priming the quiescent host immune system, with a consequent increase in immunotherapy response. The combination of TME radiomodulation and IT could therefore be a strategy for those patients affected by cold tumors, with limited or no response to IT. Thus, this review aims to provide an easy, rapid, and practical overview of how RT could convert the cold TME and why cold tumor radiomodulation could represent an interesting strategy in combination with IT.Keywords
Funding Information
- Italian Ministry of Health—Ricerca Corrente Annual Program 2023
This publication has 35 references indexed in Scilit:
- Tumor Microenvironment as A “Game Changer” in Cancer RadiotherapyInternational Journal of Molecular Sciences, 2019
- STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse modelsJournal for ImmunoTherapy of Cancer, 2019
- Topography of cancer-associated immune cells in human solid tumorseLife, 2018
- Abscopal effect of radiotherapy combined with immune checkpoint inhibitorsJournal of Hematology & Oncology, 2018
- Tumor mutational burden is a determinant of immune-mediated survival in breast cancerOncoImmunology, 2018
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicityNature Communications, 2017
- In SituTumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine TreatmentsCancer Research, 2016
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaNew England Journal of Medicine, 2014
- Intratumoral Immunization: A New Paradigm for Cancer TherapyClinical Cancer Research, 2014
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human CancerImmunity, 2013